TMX Group Equity Financing Statistics - December 2021

TMX Group Equity Financing Statistics - December 2021

Toronto Stock Exchange, TSX Venture Exchange

 TMX Group today announced its financing activity on Toronto Stock Exchange and TSX Venture Exchange for December 2021 .

TSX welcomed nine new issuers in December 2021 , compared with 25 in the previous month and 10 in December 2020 . The new listings were four exchange traded funds, two mining companies, two life sciences companies and one technology company. Total financings raised in December 2021 decreased 52% compared to the previous month, and were down 35% compared to December 2020 . The total number of financings in December 2021 was 56, compared with 60 the previous month and 53 in December 2020 .

For additional data relating to the number of transactions billed for TSX, please click on the following link: https://www.tmx.com/resource/en/440

TSXV welcomed 14 new issuers in December 2021 , compared with 16 in the previous month and eight in December 2020 . The new listings were 11 capital pool companies and three mining companies. Total financings raised in December 2021 increased 2% compared to the previous month, but were down 5% compared to December 2020 . There were 165 financings in December 2021 , compared with 138 in the previous month and 177 in December 2020 .

TMX Group consolidated trading statistics for December 2021 can be viewed at www.tmx.com .

Toronto Stock Exchange


December 2021

November 2021

December 2020

Issuers Listed

1,749

1,751

1,642

New Issuers Listed

9

25

10

IPOs

5

21

8

Graduates from TSXV

4

3

2

Issues Listed

2,425

2,423

2,293

IPO Financings Raised

$67,250,050

$2,328,258,567

$339,028,246

Secondary Financings Raised

$1,247,278,543

$2,479,445,842

$3,479,516,201

Supplemental Financings Raised

$1,190,475,684

$436,147,496

$47,308,800

Total Financings Raised

$2,505,004,277

$5,243,851,905

$3,865,853,247

Total Number of Financings

56

60

53

Market Cap Listed Issues

$4,223,871,393,563

$4,098,383,716,196

$3,398,550,102,622

Year-to-date Statistics


2021

2020

% change

New Issuers Listed

213

170

+25.3

IPOs

157

140

+12.1

Graduates from TSXV

36

20

+80.0

IPO Financings Raised

$10,487,796,183

$6,759,887,738

+55.1

Secondary Financings Raised

$28,374,208,875

$27,199,147,749

+4.3

Supplemental Financings Raised

$7,054,778,977

$2,220,900,538

+217.7

Total Financings Raised

$45,916,784,035

$36,179,936,025

+26.9

Total Number of Financings

641

533

+20.3

Market Cap Listed Issues

$4,223,871,393,563

$3,398,550,102,622

+24.3

TSX Venture Exchange **


December 2021

November 2021

December 2020

Issuers Listed

1,892

1,899

1,889

New Issuers Listed

14

16

8

IPOs

13

9

5

Graduates to TSX

4

3

2

Issues Listed

2,000

2,011

1,974

IPO Financings Raised

$10,012,922

$70,656,617

$12,042,642

Secondary Financings Raised (1)

$235,851,660

$177,743,941

$370,556,898

Supplemental Financings Raised

$665,389,223

$644,211,413

$576,022,238

Total Financings Raised

$911,253,805

$892,611,971

$958,621,778

Total Number of Financings

165

138

177

Market Cap Listed Issues

$102,467,123,398

$101,455,114,372*

$78,362,951,154

Year-to-date Statistics


2021

2020

% Change

New Issuers Listed

147

63

+133.3

IPOs

101

39

+159.0

Graduates to TSX

36

20

+80.0

IPO Financings Raised

$269,665,407

$213,018,283

+26.6

Secondary Financings Raised (1)

$3,621,917,540

$1,879,583,265

+92.7

Supplemental Financings Raised

$7,138,371,483

$4,570,886,951

+56.2

Total Financings Raised

$11,029,954,430

$6,663,488,499

+65.5

Total Number of Financings

1,684

1,717

-1.9

Market Cap Listed Issues

$102,467,123,398

$78,362,951,154

+30.8


*correction


**Includes NEX (not applicable to New Issuers Listed, IPOs and IPO Financings Raised)


(1)      Secondary financings include prospectus offerings on both a  treasury and secondary basis

TMX Group does not guarantee either the completeness or the accuracy of this information. The information contained in this media release is provided for informational purposes only and you agree not to rely upon the information contained in this media release for any trading, business, or financial purposes.  By using this media release, you expressly agree to the condition that TMX Group assumes no liability or responsibility for any errors or inaccuracies in this media release.

TMX Group welcomes the following companies that listed during December 2021 :

Toronto Stock Exchange

Issuer Name

Company Symbol

Aclara Resources Inc.

ARA

BMO Money Market Fund

ZMMK

BriaCell Therapeutics Corp.

BCT

Fidelity Advantage Bitcoin ETF

FBTC & FBTC.U

Givex Information Technology Group Limited

GIVX

Horizons GX Cybersecurity Index ETF

HBUG

Horizons GX Telemedicine and Digital Health Index ETF

HDOC

Numinus Wellness Inc.

NUMI

Orezone Gold Corporation

ORE

TSX Venture Exchange

Issuer Name

Company Symbol

ECC Ventures 5 Corp.

ECCV.P

ECC Ventures 6 Corp.

ECCS.P

EV Nickel Inc.

EVNI

Fairplay Ventures Inc.

FPY.P

Fountainhall Capital Corp.

FUN.P

Gold Basin Resources Corporation

GXX

Harmony Acquisitions Corp.

MONY.P

New Media Capital 2.0 Inc.

NEME.P

PC 1 CORP.

PCAA.P

Roshni Capital Inc.

ROSH.P

Rumbu Holdings Ltd.

RMB.P

Rupert's Crossing Capital Inc.

RUCC.P

Taura Gold Inc.

TORA

Wittering Capital Corp.

WITT.P

About TMX Group (TSX:X)

TMX Group operates global markets, and builds digital communities and analytic solutions that facilitate the funding, growth and success of businesses, traders and investors. TMX Group's key operations include Toronto Stock Exchange , TSX Venture Exchange , TSX Alpha Exchange , The Canadian Depository for Securities , Montréal Exchange , Canadian Derivatives Clearing Corporation , and Trayport which provide listing markets, trading markets, clearing facilities, depository services, technology solutions, data products and other services to the global financial community. TMX Group is headquartered in Toronto and operates offices across North America (Montréal, Calgary , Vancouver and New York ), as well as in key international markets including London and Singapore . For more information about TMX Group, visit our website at www.tmx.com . Follow TMX Group on Twitter: @TMXGroup .

SOURCE TMX Group Limited

Cision View original content: https://www.newswire.ca/en/releases/archive/January2022/11/c2893.html

News Provided by Canada Newswire via QuoteMedia

BCT:CA
The Conversation (0)
BriaCell Partners with New York Cancer & Blood Specialists  for Pivotal Phase 3 Study of Bria-IMT in Advanced Breast Cancer

BriaCell Partners with New York Cancer & Blood Specialists for Pivotal Phase 3 Study of Bria-IMT in Advanced Breast Cancer

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce a partnership with New York Cancer & Blood Specialists (NYCBS), a group of... Keep Reading...
BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT in Advanced Metastatic Breast Cancer

BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT in Advanced Metastatic Breast Cancer

The randomized pivotal Phase 3 study is expected to enroll a total of 354 patients in either Bria-IMT™ combination or physician's choice therapy (1:1) Positive results of the pivotal Phase 3 study could result in full approval and marketing authorization for Bria-IMT™ The study's primary... Keep Reading...
BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

Median overall survival of 13.5 months in BriaCell's advanced metastatic breast cancer patients (vs. 6.7-9.8 months for similar patients reported in the literature) 21 out of 29 patients treated since 2022 are still alive suggesting a strong survival benefit for BriaCell's combination regimen No... Keep Reading...
BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders

BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders

briacell therapeutics corp. closes Arrangement effecting the distribution described in the plan of arrangement. briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (" BriaCell " or the " Company "), a clinical-stage biotechnology company that develops novel immunotherapies to transform... Keep Reading...
BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT in High-Risk Early-Stage Triple Negative Breast Cancer

BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT in High-Risk Early-Stage Triple Negative Breast Cancer

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has accepted a letter of intent from Dr. Massimo Cristofanilli, Director of Breast... Keep Reading...

Latest Press Releases

Related News